Patent intelligence · US
US 6165738
Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase
Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase
Patent details — US 6165738
- Jurisdiction
- US
- Status
- expired
- Grant date
- Dec 26, 2000
- Expiration
- Dec 21, 2020
- Applicant
- Montech Medical Developments Pty. Ltd.
- Claims
- 23
- CPC classes
- A61K, A61K38/00, A61P, A61P3/10
Quick answer
US 6165738 (Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase) is held by Montech Medical Developments Pty. Ltd.. Status: expired. Granted Dec 26, 2000. Expires Dec 21, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Montech Medical Developments Pty. Ltd.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K38/00, A61P, A61P3/10
More from Montech Medical Developments Pty. Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 6165738?
US 6165738 (Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase) is held by Montech Medical Developments Pty. Ltd.. Status: expired. Granted Dec 26, 2000. Expires Dec 21, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6165738?
Montech Medical Developments Pty. Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 6165738 expire?
Our index shows an expiration date of Dec 21, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.